BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

...Retrophin, which Martin Shkreli founded in 2011, is now turning its focus to renal candidate sparsentan...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...II Bristol-Myers Squibb Co. (NYSE:BMY) / Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Retrophin Inc. (NASDAQ:RTRX) Sparsentan (RE-021...
BioCentury | Sep 12, 2016
Clinical News

Sparsentan: Phase II data

...or 200, 400 or 800 mg oral sparsentan. In patients who received mid- or high-dose sparsentan...
...individual sparsentan doses “showed clear signals of relative improvement, but did not reach statistical significance.” Sparsentan...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567...
BioCentury | Sep 7, 2016
Clinical News

Retrophin jumps on Phase II FSGS data

...combined data from the three cohorts of the Phase II DUET study showed sparsentan ( RE-021...
...often leads to end-stage renal disease. Patients who received 200, 400 and 800 mg oral sparsentan...
...AGTR1 ) antagonist commonly prescribed to treat FSGS and proteinurea (p=0.006). Retrophin said the individual sparsentan...
BioCentury | Jul 11, 2016
Finance

Rethinking risk

...results this quarter from the Phase II DUET trial of Retrophin Inc .'s sparsentan ( RE-021...
...3Q16; 10/30/16 Retrophin Inc. (NASDAQ:RTRX) / Ligand Pharmaceuticals Inc. (NASDAQ:LGND) / Bristol-Myers Squibb Co. (NYSE:BMY) Sparsentan...
BioCentury | Apr 11, 2016
Clinical News

Sparsentan: Completed Phase II enrollment

...eligible to receive RE-021 in an open-label extension. Retrophin has an exclusive, worldwide sublicense to RE-021...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Sparsentan ( RE-021 ) (formerly PS433540 , BMS-456567...
BioCentury | Jan 13, 2014
Finance

Buyside View XXII: 'Grown up' means growth

...Retrophin Inc. , which Schwarz said "not many investors have on their radar." Lead program RE-021...
BioCentury | Aug 19, 2013
Finance

Highlights of weekly biotech stock moves

...commercialize an autism and schizophrenia product. Details are not disclosed. Retrophin's most advanced product is RE-021...
BioCentury | Aug 19, 2013
Company News

Retrophin deal

...to develop and commercialize a product for autism and schizophrenia. Retrophin's most advanced product is RE-021...
...to evaluate RE-021 to treat focal segmental glomerulosclerosis. Retrophin has an exclusive, worldwide sublicense to RE-021...
BioCentury | Aug 16, 2013
Company News

Retrophin raises $25M, negotiating for neurology product

...to develop and commercialize a product for autism and schizophrenia. Retrophin's most advanced product is RE-021...
...to evaluate RE-021 to treat focal segmental glomerulosclerosis. Retrophin has an exclusive, worldwide sublicense to RE-021...
Items per page:
1 - 10 of 50